Keywords: Orphan drugs, Economic viability, Revenue potential, Thomson Reuters

Study confirms economic viability of orphan drugs positioned for unmet medical needs

Article | 22 August 2012

Orphan drugs achieve blockbuster status in 2011 and generate over $50 billion in revenue, according to the results of a study by ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in